Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024

6/5/24 3:29:58 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ALGS alert in real time by email

Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (90%) HBeAg-positive CHB subjects with no viral breakthrough. New data also showed that as HBeAg declined to near negativity in this patient population, anti-HBe antibody (HBeAb) levels exhibited a positive trend.

Get the next $ALGS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALGS

Date	Price Target	Rating	Analyst
8/19/2024	$75.00	Buy	H.C. Wainwright
1/6/2023	$2.00 → $3.00	Neutral → Overweight	Piper Sandler
1/6/2023	$2.50 → $3.00	Hold → Buy	Jefferies
3/23/2022	$15.00 → $4.00	Overweight → Neutral	Piper Sandler
3/11/2022	$47.00 → $15.00	Overweight	Piper Sandler
3/11/2022	$10.00 → $11.00	Outperform	SVB Leerink
2/16/2022	$15.00 → $10.00	Outperform	SVB Leerink
1/7/2022	$30.00 → $12.00	Overweight → Neutral	JP Morgan

More analyst ratings

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. The clinical poster presentation highlighted the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) virus infection in both HBeAg-positive and HBeAg-negative subjects, de
11/19/24 1:30:41 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. "This quarter we reached a key milestone when we announced the positive topline HERALD data in MASH subjects," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "With placebo-adjusted median relative reductions in liver fat of up to 46.2%, we continue to believe ALG-055009 has best-in-c
11/6/24 4:05:39 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's third quarter 2024 financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven appro
10/30/24 4:05:00 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig
9/19/24 8:00:00 AM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th
9/18/24 5:00:00 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient
3/10/22 4:05:00 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Aligos Therapeutics Appoints David Perry as Vice President of Business Development
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline
10/1/24 8:00:00 AM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
9/24/24 8:00:00 AM ET
$ALGS
$HAE
$NVO
$PLRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Aligos Therapeutics Strengthens Board with Two New Independent Directors
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", the "Company"))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. "We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors," stated
8/8/24 4:05:00 PM ET
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024

Chat with this insight

Recent Analyst Ratings for $ALGS

$ALGS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Medical Officer Achneck Hardean

SEC Form 3 filed by new insider Achneck Hardean

SEC Form 4 filed by Calhoun Lesley Ann

$ALGS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ALGS Press Releases

Fastest customizable press release news feed in the world

$ALGS Financials

Live finance-specific insights

$ALGS Leadership Updates

Live Leadership Updates

$ALGS Large Ownership Changes

This live feed shows all institutional transactions in real time.

$ALGS SEC Filings

H.C. Wainwright initiated coverage on Aligos Therapeutics with a new price target

Aligos Therapeutics upgraded by Piper Sandler with a new price target

Aligos Therapeutics upgraded by Jefferies with a new price target

Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results

Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

Aligos Therapeutics Strengthens Board with Two New Independent Directors

Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

SEC Form EFFECT filed by Aligos Therapeutics Inc.

SEC Form S-8 filed by Aligos Therapeutics Inc.

SEC Form S-3 filed by Aligos Therapeutics Inc.

$ALGS Market Insights

Live Market Insights

Aligos Therapeutics And Amoytop To Sponsor Phase 1b Study Evaluating Efficacy And Safety Of ALG-000184 With PEGBING In CHB Patients

Aligos Therapeutics To Host Key Opinion Leader Event To Discuss The Phase 1b Data From ALG-000184 For The Treatment Of CHB

Aligos Therapeutics Presented Poster Highlighting The Continued Potent Antiviral Activity Of ALG-000184 For Chronic Hepatitis B (CHB) In Both Hbeag-Positive And Hbeag-Negative Subjects At The EASL Congress 2024

Recent Analyst Ratings for
$ALGS

$ALGS
Insider Trading

$ALGS
Analyst Ratings

$ALGS
Press Releases

$ALGS
Financials

$ALGS
Leadership Updates

$ALGS
Large Ownership Changes

$ALGS
SEC Filings

$ALGS
Market Insights